The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased significantly over the past 3 decades (1). The most common site of primary GEP-NETs is the gastrointestinal tract (60%). Within the gastrointestinal tract, the single most common site is the small intestine (34%), followed by the rectum (23%), colon (19%), stomach (8%), pancreas (8%), and appendix (7%). There is no standard management of GEP-NETs, although the recent PROMID trial suggested a response benefit in the use of sandostatin LAR Depot (octreotide acetate for injection suspension; Novartis Pharmaceuticals) in patients with metastatic midgut tumors (2) . Targeted therapies, including everolimus and sunitinib, are being investigated (3) . Treatment of pancreatic neuroendocrine patients with everolimus, for example, has shown prolongation of progression-free survival (4) . Other treatment options include radiolabeled somatostatin analogs and surgical debulking; however, no improvements in survival have been reported, and validated biomarkers for response are lacking.
Currently somatostatin-receptor (sstr) imaging is the method of choice for the staging of GEP-NETs. Somatostatin [H-Ala 1 -Gly 2 -c(Cys 3 -Lys 4 -Asn 5 -Phe 6 -Phe 7 -Trp 8 -Lys 9 -Thr 10 -Phe 11 -Thr 12 -Ser 13 -Cys 14 ) -OH] is a small regulatory peptide that has an inhibitory effect on the production of several exocrine hormones (prolactin, insulin, glucagon, and thyroid-stimulating hormone) in the gastrointestinal tract and antiproliferative effects. sstrs are G-proteincoupled receptors expressed on cell membranes, which on ligand binding generate a transmembrane signal. Five receptor subtypes (sstr-1-sstr-5) have been identified to date (5) . GEP-NETs frequently express a high density of sstr, in particular sstr-2, that can be exploited for imaging, from identifying a small primary lesion after biochemical syndrome diagnosis and selecting patients for radiotherapy to exploring the extent of metastatic disease (6) (7) (8) . Somatostatin analogs have been developed because somatostatin itself has a short plasma half-life (;3 min). The current somatostatin receptor-based clinical standard for functional imaging of GEP-NETs is scintigraphy with 111 In-diethylenetriaminepentaacetic acid (DTPA)-octreotide (half-life of 111 In, 2.8 d; photon energy, 254 keV) (9) ; clinical imaging is then performed at 1-2 d after injection of the radiopharmaceutical to ensure sufficient target-to-background contrast. Octreotide [(D)-Phe 1 -c(Cys 2 -Phe 3 -(D)-Trp 4 -Lys 5 -Thr 6 -Cys 7 )Thr-ol 8 ] binds with high affinity to sstr-2 and to a lesser extent sstr-5 (10 (8, 11, 12) .
PET offers better image contrast than scintigraphy, and indeed octreotide analogs using radiometals such as 68 Ga (1.1-h half-life, 90% b 1 , 1.9-MeV E b1 [positron energy]) and 64 Cu (12.7-h half-life, 19% b 1 , 0.6-MeV E b1 ; also emission of 30% b 2 particles) have been developed for peptide-based imaging by PET (13) (14) (15) . A good correlation between the uptake of 68 Ga-labeled peptides and sstr-2 immunohistochemistry has been demonstrated in patients, supporting the use of these radioligands for imaging of sstr-2 (16) . Peptides labeled with the 18 F radioisotope, having the optimal combination of half-life, photon flux, and photon energy (1.8-h half-life, 97% b 1 , 0.6-MeV E b1 ), should be superior to the metal-based tracers and be devoid of nonspecific uptake resulting from transchelation (17) . Consequently, 18 F-labeled octreotide analogs have previously been developed (18) (19) (20) . Tyr 3 -octreotate has been radiolabeled with both 68 Ga and 18 F radioisotopes for PET of tumors (21, 22) . In this article, we explored the relatively new copper-catalyzed azide-alkyne cycloaddition reaction (click reaction) to design several octreotate analogs. Marik and Sutcliffe (23) , and Glaser and Å rstad (24) were the first to apply click chemistry to 18 F radiolabeling of various building blocks or peptides. Since then, the click reaction has been used for rapid chemoselective and regiospecific 18 F radiolabeling of peptides under mild reaction condition, with good synthetic yields (25, 26) . The Tyr 3 -octreotate core was selected over octreotide because of its superior sstr-2 specificity, higher affinity, and tumor uptake properties (8, 12) . Rapid tumor accumulation, together with rapid clearance of labeled peptides from normal tissues including the liver and muscle, is a prerequisite for use of short-lived positron-emitting radioisotopes such as 18 F. Recognizing that incorporation of polyethylene glycol (PEG) moiety and length or type of linker used to connect the peptide core to the 18 F-containing prosthetic group can change peptide disposition, we performed a comparative study to evaluate tissue pharmacokinetics and imaging properties of 5 structurally related 18 F-fluoroethyltriazole-Tyr 3 -octreotate (FET-TOCA) analogs-FET-G-PEG-TOCA, FETE-PEG-TOCA, FET-G-TOCA, FETE-TOCA, and FET-bAG-TOCA ( ½Fig: 1 Fig. 1 )-and compared these to a scrambled labeled peptide, the recently described 18 F-aluminum fluoride NOTA-octreotide ( 18 F-AIF-NOTA-OC (19) ) and the clinically used radiotracer 68 Ga-DOTATATE. Assessment of the pharmacokinetics and imaging properties in vivo should provide structure-activity relationship data for selection of the optimal radiotracer.
MATERIALS AND METHODS

Radiochemicals and Log D Measurements
Five structurally related 19 F/ 18 F fluoroethyltriazole-Tyr 3 -octreotate analogs (Supplemental Fig. 1 ; supplemental materials are available online only at http://jnm.snmjournals.org) and a related scrambled peptide were prepared. All commercially available chemicals were of analytic grade and used without further purification. Stable 19 F was used for assays in which radioactivity was not needed. The synthesis of the radiotracers by click radiochemistry (Supplemental Fig. 1 ) is reported in detail elsewhere (27) . Labeled products were eluted with ethanol in 100-mL fractions and made up to a 10% ethanol/phosphate-buffered saline solution (pH 7.4). 18 F-AIF-NOTA was synthesized as previously described (19) . 68 Ga-DOTATATE was purchased from Covidien (U.K.) Commercial Ltd. The lipophilicity (Log D) of the radiotracers has been reported (27) .
In Vitro Binding Assay
Tyr 3 -octreotate analogs bind mainly to sstr-2. The affinity of stable 19 F-fluoroethyltriazole-Tyr 3 -octreotate analogs for somatostatin receptor subtype sstr-2, versus sstr-4 as control low-affinityreceptor subtype, was determined using a fluorometric imaging plate reader assay. The assay involved measuring the 19 F-fluoro-FIGURE 1. Affinity profiles of different 18 Ffluoroethyltriazole-Tyr 3 -octreotate analogs for sstr subtypes sstr-2 (A) and sstr-4 (B), determined using calcium flux fluorometric imaging plate reader assay as described in "Materials and Methods" section. Assay was performed in duplicate. Fluorescence output was measured and data expressed as percentage maximal fluorescence signal.
ethyltriazole-Tyr 3 -octreotate-induced activation of a calcium flux in sstr-2-or sstr-4-expressing Chem-1 cells (Millipore) that were preloaded with a calcium dye. Briefly, Chem-1 cells expressing a specific sstr subtype were seeded in 96-well plates at 50,000 cells per well and incubated in 5% CO 2 for 24 h. Cells were washed and loaded with Fluo-8-No-Wash Ca 21 dye in GPCRProfiler Assay Buffer (Millipore) for 90 min at 30°C in a 5% CO 2 incubator. Different concentrations of 19 F-fluoroethyltriazole-Tyr 3 -octreotate or somatostatin (Sigma; positive control) were added, followed by fluorescence determination. The assay was performed in agonist mode in duplicate. Fluorescence output was measured and data expressed as percentage maximal fluorescence signal after baseline correction. The half maximal receptor activation for the various ligands was estimated by sigmoid dose-response fitting using GraphPad Prism (version 4.00; GraphPad Software) for Windows (Microsoft).
Animals and Tumor Models
Six-to 8-wk-old female BALB/c nu/nu athymic mice were obtained from Harlan United Kingdom Ltd. High-sstr-2 pancreatic tumor cell line AR42J (28) and low-sstr-2 human colon cancer cell line HCT116 (LGC Standards) were cultured, respectively, in F12K and RPMI 1640 growth medium containing 10% (v/v) fetal bovine serum, 2 mmol/L L-glutamine, 100 units of penicillin per milliliter, and 100 g of streptomycin per milliliter and grown in a 5% CO 2 incubator at 37°C. Tumors were established by subcutaneous injection of 100 mL of phosphate-buffered saline containing 1 · In Vivo Plasma Stability of 18 F-FET-bAG-TOCA Because 18 F-FET-bAG-TOCA was the lead compound in the series, we assessed its in vivo stability. 18 F-FET-bAG-TOCA (;3.7 MBq) was injected via the tail vein into non-tumor-bearing BALB/c nu/nu mice. Blood was obtained under general isoflurane anesthesia at 30 min after injection, and plasma samples were prepared and immediately frozen on ice. For analysis, the samples were thawed and kept at 4°C immediately before use. Plasma (;0.2 mL) was clarified by addition of ice-cold methanol (1.5 mL), followed by centrifugation of the mixture (3 min, 20,000g; 4°C). The supernatant was evaporated to dryness. The residue was resuspended in high-performance liquid chromatography (HPLC) mobile phase (1.2 mL) and clarified (0.2-mm filter), and the sample (1 mL) was injected via a 1-mL sample loop onto the HPLC column. Samples were analyzed by radio-HPLC on a 1100 series HPLC system (Agilent Technologies) equipped with a g-RAM model 3 g-detector (IN/US Systems Inc.) and Laura 3 software (Lablogic) and ultraviolet detector (254 nm). A Waters mBondapak C 18 reversed-phase column (300 · 7.8 mm) stationary phase was eluted with a mobile phase comprising 67% water (0.1% trifluoroacetic acid)/33% acetonitrile (0.1% trifluoroacetic acid) delivered isocratically at 3 mL/min.
PET Studies
Dynamic PET scans were performed on a dedicated smallanimal PET scanner (Inveon PET module; Siemens Molecular Imaging Inc.) as reported previously (29, 30) . Briefly, tail veins were cannulated under general anesthesia (isoflurane). The animals were placed within a thermostatically controlled environment within the scanner; heart rate was monitored throughout the study. The mice were injected with 3.0-3.7 MBq of the different radiolabeled compounds, and dynamic PET/CT scans were acquired in list-mode format over 60 min. In the case of 18 F-FET-bAG-TOCA, blocking studies were also done, whereby radiotracer injection and imaging commenced 10 min after intravenous injection of 10 mg of unlabeled octreotide per kilogram (Sigma) to mice; this dose of octreotide was approximately 100-fold higher than the equivalent dose of unlabeled 18 F-FET-bAG-TOCA in the radiotracer injectate. The acquired data in all cases were sorted into 0.5-mm sinogram bins and 19 time frames (0.5 · 0.5 · 0.5 mm voxels; 4 · 15 s, 4 · 60 s, and 11 · 300 s) for image reconstruction. Three-dimensional regions of interest were manually defined on 5 adjacent regions: tumor, liver, kidney, muscle, or urine or bladder (each 0.5 mm in thickness). Data were averaged for tissues at each of the 19 time points to obtain timeactivity curves. Radiotracer uptake for each tissue was normalized to injected dose and expressed as percentage injected activity per milliliter of tissue (%ID/mL).
Direct Counting of Tissue Radioactivity
After the 60-min PET scan, a part of the tumor tissue was obtained from mice after exsanguination via cardiac puncture under general isoflurane anesthesia. All samples were weighed and their radioactivity directly determined using a Cobra II Autogamma-counter (formerly Packard Instruments) applying a decay correction. The results were expressed as a percentage injected dose per gram (%ID/g).
Statistics
Statistical analyses were performed using Prism, version 4.00 (GraphPad). Between-group comparisons were made using the nonparametric Mann-Whitney test. Two-tailed P values of 0.05 or less were considered significant.
RESULTS
Radiotracers
All radiotracers were successfully prepared with more than 98% radiochemical purity. The total synthesis time was approximately 1.5 h. Log D of the different tracers is shown in Supplemental Figure 1 .
In Vitro sstr Subtype Specificity
All the 19 F-fluoroethyltriazole-Tyr 3 -octreotate analogs exhibited agonist activity on sstr-2 ( Fig. 1 ; ½Table 1 Table 1 Given the high affinity and systemic stability of 18 F-FETbAG-TOCA, it was reassuring to observe good localization of the radiotracer in the tumor. ½Fig: 3 Figure 3A shows typical transverse and sagittal PET image slices through sstr-2-expressing AR42J tumor-bearing mice, demonstrating localization of 18 18 F-FET-bAG-[W-c-(CTFTYC)K] was injected (Fig. 3B) . In this case, tracer localization was seen mainly in the brain, urine, liver, and intestines (data not shown). The comparative pharmacokinetics of all 18 F-fluoroethyltriazole-Tyr 3 -octreotate analogs in the tumor, kidney, liver, and muscle are shown in ½Fig: 4 Figure 4 ; liver tissue data with expanded y-axis and bladder or urine data are shown in Supplemental Figure  2 . Radiotracer uptake in the AR42J tumor was characterized by a rapid increase over the entire scanning period of 60 min. 18 F-FET-G-TOCA had the highest tumor uptake, followed by 18 F-FET-bAG-TOCA, which had uptake higher than or comparable to 18 F-AIF-NOTA-OC. These tracers were superior to the clinical radiotracer 68 Ga-DOTATATE with respect to tumor uptake as well as tumor-to-muscle and tumor-to-blood ratios ( ½Table 2 Table 2 ). Because the animals were scanned on different days, the mean specific radioactivity for each radiotracer is presented ( Table 2 ). PEG linkers, embodied within the structures of 18 F-FET-G-PEG-TOCA and 18 F-FETE-PEG-TOCA, reduced tumor uptake but increased tumor-to-muscle and tumor-to-blood ratios ( Fig. 4 ; Table 2 ). Nonspecific uptake in liver was, in general, low (,7 %ID/mL), with 18 F-FETbAG-TOCA showing the lowest liver uptake; 18 F-FET-G-TOCA and 18 F-FETE-PEG-TOCA showed the highest liver uptake. The 18 F PEG-TOCA analogs had the highest urinary clearance, in keeping with their lower lipophilicity. Radiotracer kinetic profiles in the kidney, which also expresses sstr-2 (31), were different from those in tumors; however, the magnitude of uptake was highest for the 2 radiotracers 18 F-FET-bAG-TOCA and 18 F-FET-G-TOCA. The mean muscle uptake was less than 3 %ID/mL for all radiotracers. Radiotracer uptake in the bone was low for all the analogs, indicating little or no defluorination. We compared the uptake of the radiotracers in the imaging studies to direct tissue counting. The profiles were generally in agreement, but the magnitude was higher for direct counting, consistent with partial-volume averaging. Direct radioactivity determination (g-counting) of only a part of the tissue relative to sampling of the whole tumor in the case of imaging could also have led to systematic differences.
Specificity of 18 F-FET-bAG-TOCA Uptake
Given the high tumor uptake of the radiotracers, we next assessed the specificity of uptake in vivo using 18 F-FETbAG-TOCA as the prototypical 18 F-fluoroethyltriazoleTyr 3 -octreotate. We demonstrated that radiotracer uptake was specific: in keeping with the poor affinity for sstr-2, the radiolabeled scrambled peptide 18 was receptor-mediated, blocking studies were conducted by preinjecting mice with an excess of unlabeled octreotide (100-fold molar equivalent) to saturate sstr-binding sites.
This resulted in a 2-fold (by direct counting) lower uptake of 18 F-FET-bAG-TOCA in AR42J xenografts and even higher reductions in tumor-to-muscle and tumor-to-blood ratios ( Fig. 5 ; Table 2 ). After blocking with unlabeled octreotide, muscle radioactivity increased. Kidney (early time points only) decreased but subsequently increased; urine radioactivity decreased (Supplemental Fig. 3 ). Further evidence for the specificity of 18 F-FET-bAG-TOCA uptake was provided by the low uptake in low-sstr-expressing HCT116 xenografts, compared with the AR42J xenografts ( Table 2) .
DISCUSSION
We report here new 18 F-fluoroethyltriazole-Tyr 3 -octreotate radioligands that combine high specific binding with rapid target localization for high-contrast PET. Six 18 F-fluoroethyltriazole-Tyr 3 -octreotate analogs were synthesized by the click reaction, and their in vitro affinity and in vivo pharmacokinetics were investigated to enable selection of the optimal radiotracer for PET of somatostatin receptor-positive GEP-NETs. The current somatostatin receptor-based clinical standard for functional imaging, 111 In-DTPA-octreotide, suffers from low image contrast and uses a long (1-2 d) diagnostic protocol (9) . Substitution of Phe 3 by Tyr 3 on octreotide, as well as C-terminal Thr(ol) 8 by Thr, gives , with improved selectivity and affinity for sstr-2 (8, 11, 12) . We have now further modified Tyr 3 -octreotate by introducing an 18 F-labeled triazole via the click reaction (24) . For these 18 F-labeled compounds to be useful, however, they need to combine high tumor uptake with rapid low nontarget washout. We used different chain lengths, In vitro studies revealed that the triazole analogs had high selective affinity to sstr-2, with half-maximal agonist activity in the calcium flux assay for this G-protein-coupled receptor (EC 50 ) ranging from 4 to 19 nM, compared with the scrambled peptide, which had a low affinity. The combined effect of high binding affinity for sstr and rapid washout from nontarget tissue produced high-contrast PET images in vivo, demonstrated for 18 F-FET-bAG-TOCA in Figure 3 . The increasing tumor time versus activity curves of 18 F-FET-bAG-TOCA derived from the in vivo dynamic PET image data (Fig. 4) reflected the high selective binding of 18 F-FET-bAG-TOCA. The radiotracer was metabolically stable in mice and was not defluorinated. Overall, we observed that 18 F-fluoroethyltriazole-Tyr 3 -octreotate radiotracer pharmacokinetics was modified by the structural changes. For example, 18 F-FET-G-TOCA that differed in 1 amino acid group (b-alanine) from 18 F-FET-bAG-TOCA showed higher tumor uptake and higher nonspecific tissue uptake. This observation may be because of the higher lipophilicity of FET-G-TOCA. Use of ethylene ( 18 F-FET-G-TOCA) instead of amide linker ( 18 F-FETE-TOCA) led to differences in tumor uptake, despite similar sstr-2 agonist affinities in vitro. Thus, chain length and linker type affects pharmacokinetics, but we did not have enough Data are mean 6 SE, n 5 3-6. Imaging data are presented for 60-min time point together with tissue data obtained from counting pieces of tissue directly in g-counter soon after imaging study. In vivo 18 F-FET-bAG-TOCA blocking studies were done after intravenous injection of unlabeled octreotide (10 mg/kg) to mice, followed 10 min later by injection of radiotracer. analog data to predict the mechanisms underpinning this effect.
Interestingly, the tumor uptake for 18 F-FET-G-TOCA and 18 F-FET-bAG-TOCA compounds ranked among the highest reported to date and was higher than that of 68 Ga-DOTATATE (Table 1) , which is used clinically. Similarly the tumor uptake of the two 18 F-fluoroethyltriazole-Tyr 3 -octreotate analogs was significantly higher than those reported for 111 In-DTPA-octreotide by Froidevaux et al. in the same tumor model (3.03 6 0.26 %ID/g) (32) . The tracers also showed uptake similar to or higher than 18 F-AIF-NOTA-OC. In contrast to the high tumor uptake of 18 F-FET-G-TOCA and 18 F-FET-bAG-TOCA, the 2 PEGylated analogs showed lower tumor uptake. Because of reduced glomerular filtration, PEGylation of peptides reduces their overall clearance from the body and increases half-life. We used only small PEG groups of approximately 0.3 kDa, which may not be large enough to affect glomerular filtration. PEGylation also makes compounds more water-soluble (33), supporting faster clearance from the circulation than with the less hydrophilic non-PEGylated analogs. The high urinary clearance of our PEGylated analogs (Supplemental Fig. 2 ) and high tumor-to-muscle and tumor-to-blood ratios supported the latter mechanism. The low overall tumor uptake of the PEG-TOCA analogs could also be explained by their lower in vitro affinity ( Fig. 1 ; Table 1 ).
It was predicted that liver tissue that generally shows low 111 In-DTPA-octreotide uptake (34) will also show low uptake of the 18 F-fluoroethyltriazole-Tyr 3 -octreotate radiotracers. The PEG-TOCA analogs had lower liver uptake. Interestingly, 18 F-FET-bAG-TOCA, with intermediate hydrophilicity, compared with the PEGylated analogs (Supplemental Fig. 1 ), showed similar low uptake in liver, a positive attribute of 18 F-FET-bAG-TOCA that was not realized in 18 F-FET-G-TOCA. High nonspecific liver uptake could reduce specificity of imaging agents for detecting metastatic liver disease. 18 F-FET-G-TOCA had high liver uptake, making it less attractive for imaging metastatic disease despite showing the highest tumor uptake. Because of its high specificity, characterized by high tumor uptake and tumor-to-muscle ratio but comparatively low background (liver) uptake, we selected 18 F-FET-bAG-TOCA for further evaluation.
Evidence from the blocking studies and poor uptake in low-sstr tumors with respect to 18 F-FET-bAG-TOCA, as well as low tumor uptake of the scrambled peptide, indicated that the uptake of 18 F-FET-bAG-TOCA was receptormediated. The in vivo blocking study showed that injecting unlabeled octreotide partially reduced tumor uptake of 18 F-FET-bAG-TOCA in the AR42J model. Muscle and liver retained higher radioactivity levels with blocking, possibly because of reduced elimination into urine. Interestingly, the kidney uptake normalized at late time points after blocking. The kidney is a complex organ regarding uptake of somatostatin analogs. The kidney profile observed in our dynamic study may be due to a mix of receptor-mediated and non-receptor-mediated effects (35) . For radiometal-labeled octreotide analogs, non-receptor-mediated mechanisms appear to dominate uptake (36) . The mechanism for the nonreceptor-mediated renal uptake is generally assumed to involve charge-dependent endocytosis in kidneys; in keeping with this assumption, coinfusion of basic amino acids selectively reduces accumulation in kidneys (20, 37, 38) . Other radiometal-labeled peptides including bombesin also show high kidney uptake; however, kidney uptake of labeled peptides is modified by the radioactive label used. Indeed, work by Liu et al. showed that for radiolabeled bombasin, renal uptake decreases in the order 64 Cu . 68 Ga .. 18 F. Therefore, for 18 F-octreotate analogs, specific uptake by renal sstr-2 may contribute significantly to uptake, explaining the initial reduction of uptake in kidneys after injection of excess unlabeled octreotide. We also interpret the low renal uptake of the scrambled peptide that had poor in vitro affinity for sstr-2 as resulting at least in part from low receptor binding. Excess cold octreotide may affect renal solute transport. High-dose somatostatin decreases renal plasma flow and glomerular filtration rate in humans (39) ; the same effect would be expected of other agonists in the mouse given expression of sstr-2 in mouse kidney (31) and could explain the lower urine levels after treatment with cold octreotide. Similarly, we speculate that the smaller than expected reduction in kidney radiotracer uptake at late time points after administration of excess cold ligand could be due in part to reduced renal plasma flow and glomerular filtration. Finally, uptake in AR42J was higher than that in HCT116, in keeping with the higher receptor expression in the former (sstr maximal receptor binding [Bmax], 2,482 fmol of protein per milligram for AR42J vs. 678 fmol of protein per milligram for HCT116 (28, 40) ). These studies demonstrate specificity of the radiotracers for imaging sstr-2-expressing tumors.
CONCLUSION
We report for the first time, to our knowledge, 18 F-fluoroethyl-triazole-Tyr 3 -octreotate radioligands developed via click chemistry that have good stability, high binding affinity, and optimal pharmacokinetics for imaging sstr-2-positive tumors at early time points. The prerequisite for use of short-lived positron-emitting radioisotopes involving rapid tumor accumulation together with rapid clearance of labeled peptides from normal non-sstr-expressing tissues was met but not through use of the PEG moiety. This unique multiradiotracer design and in vivo assessment has enabled us to select 2 radiotracers, 18 F-FET-bAG-TOCA and 18 F-FET-G-TOCA, as candidate sstr-2 imaging agents for clinical examination.
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